NCT06868199 - A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 6, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

February 1, 2028

Conditions

Advanced Solid Tumours

Interventions

DRUG

LM-168

Q3W,Intravenous Drip

DRUG

Toripalimab

Q3W,Intravenous

Trial Locations (6)

RECRUITING

Macquarie University, Ryde

RECRUITING

MUPharm Pty Limited trading as Macquarie University Hospital Parmarcy, Ryde

RECRUITING

Bayview Health-Investigational Drug Services, Perth

RECRUITING

One Clinical Reasearch, Perth

RECRUITING

Cancer Care Wollongong Pty Limited, Wollongong

NOT_YET_RECRUITING

Beijing Cancer Hospital, Beijing